Influenza vaccine live (MedImmune)

AIM ImmunoTech initiates development of Ampligen as a vaccine adjuvant for avian influenza, partnering with Amarex Clinical Research for IND application management.

The FDA has approved FluMist, the first influenza vaccine for at-home use, expanding access beyond traditional healthcare settings.

The FDA has approved FluMist, the first influenza vaccine for at-home use, administered as a nasal spray, for individuals aged 2-49 years.

The FDA has approved FluMist, a nasal spray flu vaccine, for self- or caregiver-administration, making it the first flu vaccine with this capability, indicated for individuals aged 2 to 49 years.

The FDA has approved FluMist, a nasal spray flu vaccine, for self-administration, marking the first flu vaccine that can be administered at home.